Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH2 | P25021 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | PTGIR | P43119 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304807 | 0.82 | SIGMAR1 (0.54) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL19502865 | 0.82 | SIGMAR1 (0.54) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL13547217 | 0.79 | SIGMAR1 (0.63) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL2918073 | 0.78 | SIGMAR1 (0.57) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL2916777 | 0.78 | DRD4 (0.57) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL18205232 | 0.78 | SIGMAR1 (0.57) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL1920304 | 0.77 | CMA1 (0.53) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL733605 | 0.77 | CMA1 (0.53) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL1920302 | 0.77 | CMA1 (0.53) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 | |
| SCHEMBL1920307 | 0.77 | CMA1 (0.53) | HRH2SIGMAR1SMN1; SMN2PTGIRDRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9616051-B2 | Drug targets to overcome de novo drug-resistance in multiple myeloma | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281389-A1 | NOVEL DRUG TARGETS TO OVERCOME DE NOVO DRUG-RESISTANCE IN MULTIPLE MYELOMA | XPO1, XPOT, DDB1 | HRH2 4489/4885SIGMAR1 1879/4885SMN1; SMN2 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.